News & Updates

Denosumab: A critical aspect of metastatic prostate cancer treatment

Men with metastatic prostate cancer (mPC) have an elevated risk of skeletal complications either due to bone metastases (skeletal-related events [SREs]), or from osteoporosis induced by androgen deprivation therapy (ADT). Two key opinion leaders recently shared their perspectives on bone complications in mPC as well as the use of bone-targeted agents (BTAs) such as denosumab (Xgeva) to reduce the risk of bone complications.

 

Professor Bertrand Tombal

Professor of Urology

Cliniques universitaires Saint-Luc & Université catholique de Louvain

Brussels, Belgium

 

Associate Professor Edmund Chiong

Head, Department of Urology

National University Hospital, Singapore

 

 

 

MRI provides long-term prognosis of patients with biochemical recurrence

Use of prostatectomy bed magnetic resonance imaging (MRI) can give out long-term prognostic information for assessing patients with biochemical recurrence following prostatectomy, reveals a recent study.

Apalutamide-related adverse events in prostate cancer common but manageable

Dermatological adverse events (dAEs) associated with apalutamide, though common, can be managed with topical steroids with or without oral antihistamines, reports a study.

Smoking, socioeconomic status ups LUTS risk, worsens sleep, stress in men over 40

Among men ≥40 years of age, socioeconomic status, age, and lifelong smoking all appear to be correlated with moderate-to-severe lower urinary tract syndrome (LUTS), reports a recent study. In turn, LUTS leads to worse sleep quality and stress level.

Corporotomy site of no safety consequence in IPP implantation

The location of corporotomy during the implantation of inflatable penile prostheses (IPP) does not seem to affect the incidence intraoperative or short-term postoperative complication, according to a recent study.